3/5CNBX Pharmaceuticals Inc. (CNBX): Going-concern doubt

Market data

Price before filing: $0.0003 (2026-01-13 close, split/dividend-adjusted)
Market cap at flag: $372,406 (2026-01-14) · Latest: $197,789 (2026-10-16)

What happened next

Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.

Insider trading around this filing

90 days before the flag: no open-market insider sales or purchases reported.
30 days after: none reported.

Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2025-10-16 to 2026-02-13. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.

Verified excerpt

"The Company has incurred a net loss of $ 113,719 for the three months ended November 30, 2025; and has incurred cumulative losses since inception of $ 25,382,095 . These conditions raise substantial doubt about the ability of the Company to continue as a going concern."

Quoted from the filing. Source

What this means

The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.

Source: management disclosure in Form 10-Q (period 2025-11-30)

Why this score: quarterly (unaudited) disclosure